AstraZeneca vs Bristol-Myers Squibb: Revenue, Profit and Business Model
AstraZeneca had $58.7B of annual revenue in FY2025 and $10.2B of net income. Bristol-Myers Squibb had $48.2B of annual revenue in FY2025 and $7.1B of net income.
Latest financial snapshot
AstraZeneca
- Latest annual revenue
- $58.7B (FY2025)
- Net income
- $10.2B
- Net margin
- 17.4%
- Revenue growth
- +11.0% a year, FY2016–FY2025
Bristol-Myers Squibb
- Latest annual revenue
- $48.2B (FY2025)
- Net income
- $7.1B
- Net margin
- 14.6%
- Revenue growth
- +10.6% a year, FY2016–FY2025
Financial summary
AstraZeneca
AstraZeneca's Total Revenue fell from $33.6 billion in 2011 to a trough of $22.1 billion in 2018 as Seroquel, Nexium and Crestor lost exclusivity. Under Pascal Soriot the company redirected spending into oncology and specialty medicines, and revenue then grew every year to $58.7 billion in 2025, with profit for the year of $10.2 billion and gross profit of $48.1 billion on cost of sales of $10.6 billion. R&D investment reached $14.2 billion in 2025, about a quarter of Total Revenue, and the $39 billion Alexion acquisition added a rare disease business the company did not have before 2021. AstraZeneca is a massive global biopharmaceutical company, sustaining a market valuation often exceeding $200 billion.
Bristol-Myers Squibb
Revenue grew from $19.4 billion in 2016 to $42.5 billion in 2020 as Celgene's sales were added, and has stayed between $45.0 billion and $48.3 billion since 2021. Net earnings are far less stable because BMS expenses acquired in-process R&D: the $11.4 billion MyoKardia charge produced a $9.0 billion net loss in 2020, and the Karuna charge produced an $8.9 billion loss in 2024. Cash generation is steadier, with free cash flow of about $12.8 billion in 2025. That cash funds a dividend raised for a 17th straight year in February 2026, to $0.63 a quarter, and debt reduction, from $51.2 billion at the end of 2024 to $47.2 billion a year later. On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion, from $46.0 to $47.5 billion, after second-quarter revenue rose 6 percent to $12.97 billion. Bristol Myers Squibb is a dominant force in global biopharmaceuticals, sustaining a massive market valuation that regularly exceeds $100 billion.
Revenue and profit by year
AstraZeneca
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $58.7B | $10.2B | 17.4% | +8.6% | Source |
| FY2024 | $54.1B | $7B | 13.0% | +18.0% | Source |
| FY2023 | $45.8B | $6B | 13.0% | +3.3% | Source |
| FY2022 | $44.4B | $3.3B | 7.4% | +18.5% | Source |
| FY2021 | $37.4B | $115M | 0.3% | +40.6% | Source |
| FY2020 | $26.6B | $3.1B | 11.8% | +9.2% | Source |
| FY2019 | $24.4B | $1.2B | 5.0% | +10.4% | Source |
| FY2018 | $22.1B | $2B | 9.3% | -1.7% | Source |
| FY2017 | $22.5B | $2.9B | 12.8% | -2.3% | Source |
| FY2016 | $23B | $3.4B | 14.8% | — | Source |
Bristol-Myers Squibb
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $48.2B | $7.1B | 14.6% | -0.2% | Source |
| FY2024 | $48.3B | -$8.9B | -18.5% | +7.3% | Source |
| FY2023 | $45B | $8B | 17.8% | -2.5% | Source |
| FY2022 | $46.2B | $6.3B | 13.7% | -0.5% | Source |
| FY2021 | $46.4B | $7B | 15.1% | +9.1% | Source |
| FY2020 | $42.5B | -$9B | -21.2% | +62.6% | Source |
| FY2019 | $26.1B | $3.4B | 13.2% | +15.9% | Source |
| FY2018 | $22.6B | $4.9B | 21.8% | +8.6% | Source |
| FY2017 | $20.8B | $1B | 4.8% | +6.9% | Source |
| FY2016 | $19.4B | $4.5B | 22.9% | — | Source |
Where the revenue comes from
AstraZeneca
- Product Sales~95%
Product Sales were $55,573 million in 2025, up 9%, or about 95% of Total Revenue. This is the direct sale of AstraZeneca-manufactured prescription medicines to wholesalers, pharmacies, hospitals and government buyers. Oncology was the largest therapy area at roughly $25.6 billion of revenue, up 17%, followed by Cardiovascular, Renal and Metabolism, with Respiratory and Immunology and Rare Disease making up most of the balance.
- Alliance Revenue~5%
Alliance Revenue was $3,067 million in 2025, up 39%, or about 5% of Total Revenue. It is mostly AstraZeneca's share of profits on co-commercialised medicines, led by the Enhertu and datopotamab deruxtecan antibody-drug conjugates developed with Daiichi Sankyo, plus Tezspire with Amgen and Lynparza and Koselugo with Merck in certain markets.
- Collaboration Revenue<1%
Collaboration Revenue was $99 million in 2025, down 89% from $923 million in 2024, so less than 1% of Total Revenue. It covers upfront fees, milestone payments and royalties on out-licensed assets, and moves sharply year to year because it depends on when individual deals are signed.
Bristol-Myers Squibb
- Growth Portfolio~55%
$26.4 billion in 2025, up 17%: Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag, Camzyos, Sotyktu, Cobenfy, Krazati and other newer brands. It grew another 15% to $7.56 billion in the second quarter of 2026.
- Legacy Portfolio~45%
$21.8 billion in 2025: Eliquis ($14.4 billion), Revlimid ($3.0 billion), Pomalyst/Imnovid ($2.7 billion), Sprycel, Abraxane and other mature brands facing generic competition. Legacy revenue fell 4% in the second quarter of 2026.
Business model and strategy
AstraZeneca
How it makes money
AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company that discovers, manufactures, and markets innovative prescription medicines across four core therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Diseases. The company's business model is centered on precision medicine and targeted biologics.
Growth strategy
AstraZeneca's growth strategy relies on extending its existing cancer drugs into earlier stages of treatment, before the cancer spreads, which increases the number of patients who can be treated. The $39 billion acquisition of Alexion Pharmaceuticals in 2021 also took it into rare diseases, where drugs treat small patient populations, carry high prices and face little generic competition.
Competitive advantage
AstraZeneca's competitive moat is anchored by its scientific leadership in precision oncology, its pioneering partnership with Daiichi Sankyo on HER2-directed antibody-drug conjugates, and Alexion's proprietary complement inhibition biology.
Bristol-Myers Squibb
How it makes money
Bristol Myers Squibb Company (BMS) discovers, develops, and delivers innovative medicines across four core therapeutic areas: Oncology, Hematology, Cardiovascular, and Immunology. Commercial revenues are categorized into a Legacy Blockbuster Portfolio and a high-growth New Product Portfolio.
Growth strategy
BMS is pursuing growth on three fronts. First, scaling the Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag, Cobenfy and others), which rose 17 percent to $26.4 billion in 2025 and 15 percent to $7.56 billion in the second quarter of 2026.
Competitive advantage
Bristol Myers Squibb's competitive moat is founded on deep clinical leadership in immuno-oncology, pioneering CAR-T cell therapy manufacturing, and a first-in-class neuroscience mechanism for psychiatric disorders. By discovering and developing Opdivo and Yervoy, BMS pioneered dual checkpoint inhibition in oncology.
Questions about AstraZeneca vs Bristol-Myers Squibb
Which company has higher revenue — AstraZeneca PLC or Bristol-Myers Squibb Company?
AstraZeneca PLC had $58.7B (FY2025), while Bristol-Myers Squibb Company had $48.2B (FY2025). By latest annual revenue, AstraZeneca PLC is the larger business, with Bristol-Myers Squibb Company showing a smaller revenue base.
What is the market cap of AstraZeneca PLC vs Bristol-Myers Squibb Company?
AstraZeneca PLC's market capitalisation stands at $254.6B, while Bristol-Myers Squibb Company's is $127.5B. AstraZeneca PLC carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Bristol-Myers Squibb Company.
How does revenue per employee compare for AstraZeneca PLC and Bristol-Myers Squibb Company?
AstraZeneca PLC has $611k / employee in revenue per employee, while Bristol-Myers Squibb Company has $1.48M / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.
How do AstraZeneca PLC and Bristol-Myers Squibb Company make money?
AstraZeneca PLC and Bristol-Myers Squibb Company generate revenue in fundamentally different ways. AstraZeneca PLC: AstraZeneca PLC is a British-Swedish multinational biopharmaceutical company that discovers, manufactures, and markets innovative prescription medicines across four core therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Diseases. Bristol-Myers Squibb Company: Bristol Myers Squibb Company (BMS) discovers, develops, and delivers innovative medicines across four core therapeutic areas: Oncology, Hematology, Cardiovascular, and Immunology.
Which company is valued higher relative to revenue — AstraZeneca PLC or Bristol-Myers Squibb Company?
On a price-to-sales (P/S) basis, AstraZeneca PLC trades at 4.3x P/S and Bristol-Myers Squibb Company at 2.6x P/S. AstraZeneca PLC commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Bristol-Myers Squibb Company. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is AstraZeneca PLC bigger than Bristol-Myers Squibb Company?
By last reported revenue, AstraZeneca PLC ($58.7B (FY2025)) is the larger company compared to Bristol-Myers Squibb Company ($48.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AstraZeneca vs Bristol-Myers Squibb overview